Philips and Ibex Partnership Enhances AI in Pathology for Cancer Diagnosis
Amsterdam, Tuesday, 25 March 2025.
Philips and Ibex’s expanded partnership targets accelerated AI adoption in digital pathology, boosting cancer diagnostic efficiency by up to 37%, with new PIPS 6.0 supporting prostate, breast, and gastric cancer diagnostics.
Revolutionizing Cancer Diagnostics Through AI Integration
In a significant development announced on March 23, 2025, Royal Philips and Ibex Medical Analytics have strengthened their partnership to address the growing global shortage of pathologists and increasing cancer diagnosis demands [1]. The collaboration has demonstrated remarkable results, with their integrated digital pathology solution achieving productivity gains of up to 37% in reporting efficiency [2][3]. These improvements are particularly crucial for prostate, breast, and gastric cancer diagnostics, where precision and speed are essential for patient outcomes [1].
PIPS 6.0: Advanced Features and Clinical Workflow Enhancement
The partnership’s cornerstone advancement is the release of Philips IntelliSite Pathology Solution (PIPS) 6.0, which introduces several groundbreaking features [2]. The system now offers full scan mode for the pathology SG scanner, contextual AI launch capabilities, and a counter market tool in the image management system [2]. A notable innovation is the AI-focused worklist that displays AI processing status at the case level, while slides are automatically shared with Ibex AI applications immediately after digitization [2].
Cloud Integration and Future-Ready Infrastructure
The partnership has made strategic moves toward cloud computing integration, with Philips collaborating with Amazon Web Services (AWS) to provide cloud archival services [3]. This integration enables pathology labs to efficiently store, manage, and analyze growing volumes of digital pathology data [1]. Sam Terese, President & CEO of Alverno Laboratories, emphasizes that ‘The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis’ [1][2].
Market Impact and Implementation Status
While the partnership shows promising advancement in digital pathology, it’s important to note that these AI tools currently maintain Research Use Only (RUO) classification in the US market as of March 2025 [3]. The technology will be showcased at the US & Canadian Academy of Pathology Annual Conference in Boston from March 24-27, 2025, where healthcare professionals can experience the system’s capabilities firsthand [3]. Stéphane Rossat, Innovation & Scientific Director at Medipath, projects that ‘The enhanced interoperability between Philips and Ibex platforms will accelerate the adoption of augmented pathology tools’ [2].